Lupin announces presentation of phase 1 data on LNP7457 (PRMT5 inhibitor) at the ASCO – Annual…
Current data from Lupin indicates that LNP7457 is unique within its field and appears to be safe and well-tolerated as a…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Vinita Gupta
Lupin gets USFDA approval for Glycopyrrolate Injection, USP
The product marks the first approval from Lupin’s new injectable facility in Nagpur, India
US FDA accepts biologics license application from Lupin for pegfilgrastim biosimilar
This BLA expands the company's oncology portfolio
Lupin appoints J Alan Butcher as Chief Corporate Development Officer
Butcher will lead the company's global corporate development efforts and will be responsible for its global mergers and…
Lupin acquires Biocom in Russia
Biocom is a generic pharma company with a major focus on therapies such as cardiovascular, central nervous system and…